The following Structured Product Label (SPL) was submitted to the FDA by Patchwerx Labs, Inc. for the product Releevia Lm Patch (NDC 69329-032). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding warnings, otc - keep out of reach of children, otc - active ingredient, inactive ingredient, dosage & administration, indications & usage, otc - purpose, releevia lm patch, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
For external use only
Avoid contact with eyes
Do not applly to open wounds or damaged skin
If symptoms persist for more than seven days, discontinue use and consult physician
If swallowed, consult physician
Do not bandage tightly
If pregnant or breast feeding, contact physician prior to use
Do not use in large quantities, particularly over raw surfaces or blistered areas
Keep out of reach of children
Lidocaine HCL 4.00%
Menthol 1.00%
aloe barbadensis leaf, water, arnica montan extract, boswella serrata extract, camelia sinensis leaf extract, carbomer, ethylhexylglycerine, glycerine, isopropyl myristate, PEG 8, phenoxyethanol, polysorbate 80, sodium lauryl sulfate, triethanolamine, fd&c blue #1, fd&c yellow #5
clean and dry affected area
remove patch from backing and apply to affected area
use only one patch at a time, and maximum of four patches/day
leave patch on affected area for up to 8 hours
do not use patches for longer than five consecutive days
children under 12 should consult physician prior to use
Temporary relief of pain associated with minor cuts, scrapes and minor skin irritations
Topical anesthetic
External analgesic
Box Image (Releevia Lm Box Ndc 69329 032 15)
* Please review the disclaimer below.
